KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incyte (INCY) Gains from Sales and Divestitures (2011 - 2019)

Incyte posted quarterly Gains from Sales and Divestitures of $333334.0 for Q2 2019, up 25.0% year-on-year from $266667.0 in Q2 2018, and little changed on a QoQ basis from $333334.0 in Q1 2019.

Incyte (INCY) has 8 years of Gains from Sales and Divestitures data on file, last reported at $333334.0 in Q2 2019.

  • For the quarter ending Q2 2019, Gains from Sales and Divestitures rose 25.0% year-over-year to $333334.0; the trailing twelve-month figure through Jun 2019 stood at $333334.0 (up 25.0% YoY), and the FY2018 full-year result was $266667.0, up 33.33% from the prior year.
  • Gains from Sales and Divestitures for Q2 2019 stood at $333334.0, roughly flat from $333334.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $333334.0 in Q1 2019 and bottomed at $133333.0 in Q4 2015.
  • The 5-year median for Gains from Sales and Divestitures is $233333.5 (2017), against an average of $233333.5.
  • The widest annual swing landed in 2015, when Gains from Sales and Divestitures sank 63.29%; it then soared 50.0% in 2017.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $133333.0 in 2015, then changed by 0.0% to $133333.0 in 2016, then jumped by 50.0% to $200000.0 in 2017, then jumped by 33.33% to $266667.0 in 2018, then advanced by 25.0% to $333334.0 in 2019.
  • The last three Gains from Sales and Divestitures figures came in at $333334.0 (Q2 2019), $333334.0 (Q1 2019), and $266667.0 (Q4 2018), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2019 333,334.00
Jun 30, 2019 333,334.00
Mar 31, 2019 333,334.00
Mar 31, 2019 333,334.00
Dec 31, 2018 266,667.00
Dec 31, 2018 266,667.00
Sep 30, 2018 266,667.00
Sep 30, 2018 266,667.00
Jun 30, 2018 266,667.00
Jun 30, 2018 266,667.00
Mar 31, 2018 266,667.00
Mar 31, 2018 266,667.00
Dec 31, 2017 200,000.00
Dec 31, 2017 200,000.00
Sep 30, 2017 200,000.00
Sep 30, 2017 200,000.00
Jun 30, 2017 200,000.00
Jun 30, 2017 200,000.00
Mar 31, 2017 200,000.00
Mar 31, 2017 200,000.00
Dec 31, 2016 133,333.00
Dec 31, 2016 133,333.00
Dec 31, 2015 133,333.00
Dec 31, 2015 133,333.00
Dec 31, 2014 363,179.00
Dec 31, 2014 363,179.00
Dec 31, 2012 50,000.00
Dec 31, 2012 50,000.00
Dec 31, 2011 50,000.00
Dec 31, 2011 50,000.00